a Ming Medical Services Sdn. Bhd , Petaling Jaya , Selangor Darul Ehsan , Malaysia.
b School of Pharmacy, Faculty of Health & Medical Sciences , Taylor's University , Subang Jaya , Selangor Darul Ehsan , Malaysia.
Int Rev Immunol. 2018;37(5):266-276. doi: 10.1080/08830185.2018.1500570. Epub 2018 Sep 25.
Despite of ongoing research programs and numerous clinical trials, seasonal influenza epidemics remain a major concern globally. Vaccination remains the most effective method to prevent influenza infection. However, current flu vaccines have several limitations, including limited vaccine capacity, long production times, inconsistence efficacy in certain populations, and lack of a "universal" solution. Different next-generation approaches such as cell line-based culture, reverse genetics, and virus expression technology are currently under development to address the aforementioned challenges in conventional vaccine manufacture pipeline. Such approaches hope for safe and scalable production, induce broad-spectrum immunity, create premade libraries of vaccine strains, and target nonvariable regions of antigenic proteins for "universal" vaccination. Here, we discuss the process and challenges of the current influenza vaccine platform as well as new approaches that are being investigated. These developments indicate that an exciting future lies ahead in the influenza vaccine field.
尽管正在进行研究计划和大量临床试验，但季节性流感疫情仍然是全球关注的主要问题。疫苗接种仍然是预防流感感染的最有效方法。然而，目前的流感疫苗存在一些局限性，包括疫苗产能有限、生产时间长、在某些人群中的效果不一致，以及缺乏“通用”解决方案。目前正在开发基于细胞系的培养、反向遗传学和病毒表达技术等不同的下一代方法来解决传统疫苗制造管道中的上述挑战。这些方法希望实现安全和可扩展的生产、诱导广谱免疫、创建预先制备的疫苗株文库，并针对抗原蛋白的非可变区域进行“通用”接种。在这里，我们讨论了当前流感疫苗平台的流程和挑战以及正在研究的新方法。这些发展表明，流感疫苗领域的未来令人兴奋。
